Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation | |
|---|---|---|
| D007239 | Infection NIH | 0.05 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The inability to access and use smartphones or camera-outfitted internet-connected devices during the COVID-19 pandemic relegates certain patients to receive audio-only telemedicine instead of audio/video-based telemedicine. The investigators are conducting a randomized controlled trial in order to characterize patient and provider attitudes towards these two modalities of care and to test the feasibility of a new model to make tablets for video-based care accessible to those who need that. The investigators hypothesize that patient and provider satisfaction will be higher with video-based telehealth when compared to phone-based telehealth.
Description: Provider rating will be assessed with the Consumer Assessment of Healthcare Providers and Systems question on provider rating of 0-10; 0 being worst provider possible and 10 being best provider possible.
Measure: Provider rating as assessed by the Consumer Assessment of Healthcare Providers and Systems question on provider rating Time: Within 2 weeks of the study visitDescription: Satisfaction with telemedicine visit for patient will be assessed with Likert-scale questions related to satisfaction. Satisfaction (1=strongly disagree to 5=strongly agree). In general, I was satisfied with using a video or phone call for this visit I could explain my medical problems well enough Talking to the doctor was as satisfying as talking in person Overall score 3 to 15 with higher scores signifying better satisfaction.
Measure: Satisfaction with telemedicine visit for patient as assessed by a Likert scale Time: Within 2 weeks of the study visitDescription: Satisfaction with telemedicine visit for provider will be assessed with Likert-scale questions related to satisfaction. [1=Strongly Disagree. 5=Strongly Agree]. In general, I was satisfied with using telemedicine for this visit Talking to the patient was as satisfying as talking in person. Overall score 2 to 10 with higher scores signifying better satisfaction.
Measure: Satisfaction with telemedicine visit for provider as assessed by a Likert scale Time: Within 2 weeks of the study visitDescription: Efficacy of telemedicine visit for provider will be assessed with Likert-scale questions related to efficacy. [1=Strongly Disagree. 5=Strongly Agree]. b. I was able to understand the patient's explanation of their medical problems well enough. c. In general, this telemedicine visit was effective in improving this patient's medical care d. An in-person visit would likely have provided additional clinically-relevant information e. An in-person visit would likely have led to a change in management
Measure: Efficacy of telemedicine visit for provider as assessed by a Likert scale Time: Within 2 weeks of the study visitDescription: The ability of a provider to communicate will be assessed by patients with the yes/no question of a modified version of the Consumer Assessment of Healthcare Providers and Systems questionnaire related to communication. Did this provider explain things in a way that was easy to understand? Yes/No
Measure: Provider communication as assessed by yes/no question Time: Within 2 weeks of the study visitDescription: Provider listening will be assessed by patients with the yes/no question of a modified version of the Consumer Assessment of Healthcare Providers and Systems questionnaire related to listening. Did this provider listen carefully to you? Yes/No
Measure: Provider listening as assessed by yes/no question Time: Within 2 weeks of the study visitDescription: Provider respect will be assessed by patients with the yes/no question of a modified version of the Consumer Assessment of Healthcare Providers and Systems questionnaire relating to respect. Did this provider show respect for what you had to say? Yes/No
Measure: Provider respect as assessed by yes/no question Time: Within 2 weeks of the study visitDescription: Provider time spent will be assessed by patients with the yes/no question of a modified version of the Consumer Assessment of Healthcare Providers and Systems questionnaire relating to time spent during the clinical encounter. Did this provider spend enough time with you? Yes/No
Measure: Provider time spent as assessed by yes/no question Time: Within 2 weeks of the study visitDescription: Patient health will be assessed with Likert-scale questions related to patient health. In general, how would you rate your overall health? Excellent Very good Good Fair Poor In general, how would you rate your overall mental or emotional health? Excellent Very good Good Fair Poor Overall score 2 to 10 with lower scores signifying better health.
Measure: Patient health rating as assessed by a likert scale Time: Within 2 weeks of the study visitAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports